CURE Pharmaceutical Expands Distribution of CUREfilm Technology With First Licensing Agreement
CURE Pharmaceutical today announced it entered into a multi-year licensing agreement for the first time with a leading international cannabis company Canopy Growth Corporation (TSX: WEED) (NYSE: CGC). Under the terms of the agreement, Canopy Growth will have an exclusive license to CURE’s patented, multi-layer oral thin film (OTF), CUREfilm technology for use with cannabis extracts and biosynthetic cannabinoids in markets around the world. The parties will collaborate on new products and indications.
“Whole plant extracted, biosynthesized and synthetic cannabinoids all hold therapeutic promise for given indications and intended uses,” said Rob Davidson, CEO and Chairman of CURE Pharmaceutical. “At CURE, we focus on synthetic cannabinoids for CUREfilm products, but with our new licensing business model, we will expand the impact and applications of our technology to these other promising approaches by partnering with an industry leader in this market.”
CURE will enable the manufacturing of CUREfilms that deliver cannabis extracts, expanding the commercialization and monetization of CUREfilm technology. CURE retains the right to manufacture synthetic cannabinoids for pharmaceutical applications.
The CUREfilm license gives the Canopy Growth a dosage form that is ideal for the delivery of cannabinoids. It offers increased bioavailability, ease and precision of dosing and greater palatability. Cannabinoids are chemical compounds found in plants, such as cannabis (phytocannabinoids), synthesized by cells of the human body (endocannabinoids) or synthesized in a laboratory (biosynthetic cannabinoids) that interact with the body’s endocannabinoid system. The endocannabinoid system is recognized as an important modulatory system in the function of the brain, endocrine and immune tissues.
This is the first time CURE’s products have been manufactured outside of their Oxnard-based facility. Canopy Growth has the capacity to mass produce CUREfilms with cannabis extracts in its 5.6 million square feet facility, expanding the commercialization and monetization of CUREfilm technology.
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the US, Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced. For more information, visit www.curepharmaceutical.com.
Total Page Views: 462